These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22789834)

  • 1. Let off the leash: kala-azar following the use of tumour necrosis factor antibodies.
    Khan A; Coakley G; Cosgrove C; Lockwood D
    BMJ Case Rep; 2010 Oct; 2010():. PubMed ID: 22789834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous and visceral leishmaniasis during anti-TNFα therapy.
    Guarneri C; Bevelacqua V; Patterson JW; Tchernev G
    Wien Med Wochenschr; 2017 Mar; 167(3-4):78-82. PubMed ID: 27832423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumour necrosis factor-induced visceral and cutaneous leishmaniasis: case report and review of the literature.
    Català A; Roé E; Dalmau J; Pomar V; Muñoz C; Yelamos O; Puig L
    Dermatology; 2015; 230(3):204-7. PubMed ID: 25633623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?
    Tektonidou MG; Skopouli FN
    Clin Rheumatol; 2008 Apr; 27(4):541-2. PubMed ID: 17963018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visceral leishmaniasis in a patient taking adalimumab for rheumatoid arthritis.
    Berry CE; Tsai J; Tierney A; Pickles R
    Med J Aust; 2013 Apr; 198(6):331-3. PubMed ID: 23545033
    [No Abstract]   [Full Text] [Related]  

  • 6. Endometrium cancer in a female with psoriatic arthritis treated with TNF alpha antagonist adalimumab.
    Erten S
    Rheumatol Int; 2011 Nov; 31(11):1537-8. PubMed ID: 21120492
    [No Abstract]   [Full Text] [Related]  

  • 7. Amyotrophic lateral sclerosis developing during adalimumab therapy for psoriatic arthritis.
    Bougea A; Anagnostou E; Stamboulis E; Kararizou E
    Rev Neurol (Paris); 2014 Mar; 170(3):228-9. PubMed ID: 24656415
    [No Abstract]   [Full Text] [Related]  

  • 8. [Kala azar - Lethal course of visceral leishmaniasis. Synchronous infection with Leishmania donovani/infantum complex and Leishmania major in a patient after Mediterranean vacation].
    Posch C; Walochnik J; Gschnait A; Feichtinger H; Rappersberger K
    Hautarzt; 2012 Dec; 63(12):947-51. PubMed ID: 23064668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visceral leishmaniasis infection during adalimumab therapy: a case report and literature review.
    Tung Chen Y; Perales C; Lacruz J; Senent L; Salavert M
    Int J Rheum Dis; 2014 Sep; 17(7):822-4. PubMed ID: 24980576
    [No Abstract]   [Full Text] [Related]  

  • 10. Alopecia areata universalis elicited during treatment with adalimumab.
    Pelivani N; Hassan AS; Braathen LR; Hunger RE; Yawalkar N
    Dermatology; 2008; 216(4):320-3. PubMed ID: 18230980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double Infection in a Patient with Psoriatic Arthritis Under TNF-alpha Blockers Therapy: A Case Report.
    Caroleo B; Migliore A; Cione E; Zampogna S; Perticone F; Sarro G; Gallelli L
    Curr Drug Saf; 2019; 14(2):147-150. PubMed ID: 30648521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient.
    Lindsey SF; Weiss J; Lee ES; Romanelli P
    J Drugs Dermatol; 2014 Jul; 13(7):869-71. PubMed ID: 25007373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visceral Leishmaniasis among immunosuppressed patients with rheumatic diseases.
    Erre GL; Mesina P; Tonelli N; Passiu G
    Clin Exp Rheumatol; 2010; 28(4):590-1. PubMed ID: 20659417
    [No Abstract]   [Full Text] [Related]  

  • 14. Mycobacterium chelonae infection associated with adalimumab therapy.
    Díaz F; Urkijo JC; Mendoza F; de la Viuda JM; Blanco M; Unzurrunzaga A; Ayarza R
    Scand J Rheumatol; 2008; 37(2):159-60. PubMed ID: 18415777
    [No Abstract]   [Full Text] [Related]  

  • 15. Visceral leishmaniasis and anti-TNF-alpha therapy: case report and review of the literature.
    De Leonardis F; Govoni M; Lo Monaco A; Trotta F
    Clin Exp Rheumatol; 2009; 27(3):503-6. PubMed ID: 19604446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignancies developing in obese patients with psoriasis while on antitumour necrosis factor-α therapies: a case series.
    Sadlier M; Lally A; Kirby B
    Br J Dermatol; 2012 Oct; 167(4):937-8. PubMed ID: 22428935
    [No Abstract]   [Full Text] [Related]  

  • 17. Erythema nodosum, a "red flag" during anti-TNF therapy.
    Dalmau-Carolà J
    Int J Rheum Dis; 2013 Aug; 16(4):493-4. PubMed ID: 23992277
    [No Abstract]   [Full Text] [Related]  

  • 18. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis.
    Mease PJ
    Expert Opin Biol Ther; 2005 Nov; 5(11):1491-504. PubMed ID: 16255652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumour necrosis factor-induced cutaneous leishmaniasis in patient with psoriatic arthritis and uveitis.
    Hernandez Bel L; Hernández Garfella ML; Chiarri Toumit C; Valenzuela Oñate C
    Arch Soc Esp Oftalmol (Engl Ed); 2018 Dec; 93(12):621-622. PubMed ID: 30100239
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.